Levodopa/Carbidopa Teva

Levodopa, the active ingredient in Levodopa/Carbidopa Teva, is a Levodopa/Carbidopa combination presented as an oral tablet for oral use. It is used to treat Parkinson's disease and related Parkinsonian syndromes by restoring dopamine levels in the brain. GNH USA supplies Levodopa/Carbidopa Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa acts on the dopaminergic pathway to improve motor function in Parkinsonian disorders. - Parkinson's disease: reduces rigidity, bradykinesia and tremor, improving daily activities. - Parkinsonian syndrome: alleviates motor symptoms caused by various etiologies. - Rest tremor: diminishes tremor amplitude and frequency, enhancing patient comfort.

Levodopa/Carbidopa may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea or vomiting - Orthostatic hypotension - Dyskinesia (involuntary movements) - Dry mouth - Drowsiness or fatigue - Loss of appetite

Serious or Rare Side Effects: - Neuroleptic malignant syndrome-like reaction - Severe psychiatric disturbances (hallucinations, confusion) - Cardiac arrhythmias - Severe hypotension with syncope - Allergic skin reactions (rash, urticaria)

Before initiating therapy, consider patient‑specific factors and monitor for complications. - Renal impairment: adjust monitoring as drug is excreted renally. - Hepatic disease: use with caution due to altered metabolism. - Cardiovascular risk: monitor blood pressure and heart rate for orthostatic changes. - Psychiatric history: watch for hallucinations or mood swings. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Levodopa/Carbidopa can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may block dopaminergic effects. - High‑dose pyridoxine (vitamin B6): accelerates peripheral conversion, reducing central levodopa.

Moderate Interactions (Monitor Closely): - Iron or calcium supplements: may reduce levodopa absorption; separate dosing by at least 2 hours. - Antihypertensives: additive blood‑pressure lowering effect. - SSRIs or SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors.